Nobivac® FeLV, suspension for injection for cats
Feline leukaemia virus (FeLV) is a serious pathogen of cats. Persistent infections result in high rates of mortality, particularly in younger cats. The virus is spread by close contact between cats, including cat fight wounds, or even licking and grooming. It is also transferred from an infected queen to her kittens while they are still in the womb. The time between infection with the virus and the appearance of signs of the disease may be very long – up to several years in some cases. Infected cats can appear healthy but still be a risk of infection to others.
Presentation
Opalescent suspension for injection
Active ingredients
Nobivac FeLV is an inactivated vaccine which contains 102 µg per ml of purified p45 FeLV-envelope antigen, obtained by genetic recombination of a strain of E. coli. The antigenic suspension is adjuvanted with 1 mg of 3 % aluminium hydroxide gel and with 10 µg purified extract of Quillaja saponaria.
Target species
Cats
Indications for use
For active immunisation of healthy cats to prevent persistent feline leukaemia-virus viraemia and any associated clinical signs of feline leucosis. The onset of protection begins 2 weeks after immunisation. Following a first booster vaccination one year after the primary vaccination course, subsequent vaccinations can be performed at intervals of up to three years.
Packaging
Boxes containing 10 or 50 single dose vials of vaccine
Legal category
POM-V
Further information is available from the SPC, datasheet or package leaflet.
Advice should be sought from the medicine prescriber.
Prescription decisions are for the person issuing the prescription alone.
Use Medicines Responsibly.
Product images are representations of packaging and may not accurately reflect the current packaging available in the GB marketplace.
Date of preparation: August 2024